Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.60 |
| ▸ | AR | P10275 | 4/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26928955 | 1.00 | CRBN (0.60) | CRBNARDDB1CDK9BTK | |
| SCHEMBL26928967 | 0.95 | CRBN (0.56) | CRBNARDDB1CDK9BTK | |
| SCHEMBL30692990 | 0.95 | CRBN (0.56) | CRBNARDDB1CDK9BTK | |
| SCHEMBL27176456 | 0.92 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL25368697 | 0.90 | CRBN (0.60) | CRBNARDDB1CDK9BTK | |
| SCHEMBL29927733 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL20231763 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL29132140 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL29578907 | 0.88 | CRBN (0.58) | CRBNARDDB1CDK9BTK | |
| SCHEMBL29614670 | 0.88 | CRBN (0.58) | CRBNARDDB1CDK9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239629-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 | Plexium, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |